אינטגרילין 2 מגמל

País: Israel

Língua: hebraico

Origem: Ministry of Health

Ingredientes ativos:

EPTIFIBATIDE

Disponível em:

MERCK SHARP & DOHME (ISRAEL - 1996) COMPANY LTD, ISRAEL

Código ATC:

B01AC16

Forma farmacêutica:

תמיסה להזרקה

Composição:

EPTIFIBATIDE 2 MG/ML

Via de administração:

תוך-ורידי

Tipo de prescrição:

מרשם נדרש

Fabricado por:

SCHERING-PLOUGH LABO. N.V , BELGIUM

Grupo terapêutico:

EPTIFIBATIDE

Área terapêutica:

EPTIFIBATIDE

Indicações terapêuticas:

Integrilin is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-Q-wave myocardial infarction. Integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. Integrilin is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (PTCA) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). Integrilin is intended for use with aspirin and heparin.

Data de autorização:

2013-10-31